Figure 3.
Incidence of aGVHD, OS, and TRM according to aGVHD scores in the validation cohort. (A) The cumulative incidence of grade II-IV aGVHD among the validation cohort (n = 8050) is shown according to each risk group for grade II-IV aGVHD (Low, n = 1595; Low-Int, n = 1573; Int, n = 1661; High-Int, n = 1581; High, n = 1640). OS (B) and TRM (C) calculated for the same subgroups. (D) The cumulative incidence of grade III-IV aGVHD among the validation cohort is shown according to each risk group for grade III-IV aGVHD (Low, n = 1304, Low-Int, n = 1603; Int, n = 1922; High-Int, n = 1598; High, n = 1623). OS (E) and TRM (F) calculated for the same subgroups.

Incidence of aGVHD, OS, and TRM according to aGVHD scores in the validation cohort. (A) The cumulative incidence of grade II-IV aGVHD among the validation cohort (n = 8050) is shown according to each risk group for grade II-IV aGVHD (Low, n = 1595; Low-Int, n = 1573; Int, n = 1661; High-Int, n = 1581; High, n = 1640). OS (B) and TRM (C) calculated for the same subgroups. (D) The cumulative incidence of grade III-IV aGVHD among the validation cohort is shown according to each risk group for grade III-IV aGVHD (Low, n = 1304, Low-Int, n = 1603; Int, n = 1922; High-Int, n = 1598; High, n = 1623). OS (E) and TRM (F) calculated for the same subgroups.

Close Modal

or Create an Account

Close Modal
Close Modal